ArticleFrontiers in cardiovascular medicine2024
Hospitalizations and cardiac sarcoidosis: insights into presentation and diagnosis from the nationwide readmission database.
Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cardiac sarcoidosis (CS) is an increasingly recognized cause of cardiac disease. Because the clinical presentation of CS is non-specific, the diagnosis is often delayed. Early detection is essential to initiate treatments that reduce the risk of heart failure (HF) and arrhythmic death. We therefore aimed to describe the features of CS hospitalizations during which the initial diagnosis of CS is made. Methods: We performed a retrospective analysis of hospitalizations from 2016 to 2019 in the Nationwide Readmission Database (NRD). Hospitalizations with a primary diagnosis suggestive of CS (HF/cardiomyopathy, cardiac arrest, arrhythmias, or heart block) were categorized into cases with and without CS as a secondary diagnosis (CS+ and CS-, respectively). One-to-one propensity score matching (PSM) was performed. Results: The CS+ cohort comprised 1,146 hospitalizations and the CS- cohort 3,250,696 hospitalizations. The CS+ cohort included patients who were younger and more often male. PSM resulted in highly matched cohorts (absolute standardized mean difference <0.1). Primary diagnoses of ventricular arrhythmias (VA) or heart block were more frequent in matched CS+ hospitalizations, whereas primary diagnosis of HF/cardiomyopathy was more frequent in matched CS- hospitalizations. The matched CS+ group exhibited higher rates of in-hospital procedures and longer length of stay. In-hospital mortality and 30-day readmission were similar between matched cohorts. Discussion: These findings highlight increased rates of CS in younger males with primary diagnoses of VA and heart block, and increased use of diagnostic and therapeutic interventions such as pacemaker and left ventricular assist device implantation, and could aid clinicians in more timely diagnosis and treatment of CS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.